DRUGS & SUPPLEMENTS

Clopaz

advertisement
How long you have been taking the medicine?

Clopaz uses


1 INDICATIONS AND USAGE

Clopaz is an atypical antipsychotic indicated for:

  • Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study.
  • Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study (1.2, 14.2).

1.1 Treatment-Resistant Schizophrenia

Clopaz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clopaz should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see Warnings and Precautions (5.1, 5.5) ].

The effectiveness of Clopaz in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing Clopaz and chlorpromazine in patients who had failed other antipsychotics .

1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorders

Clopaz is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.

The effectiveness of Clopaz in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT trial .

advertisement

2 DOSAGE AND ADMINISTRATION

  • Starting Dose: 12.5 mg once daily or twice daily.
  • Use cautious titration and divided dosage schedule (2.2, 5.3).
  • Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated (2.2).
  • Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks (2.2).
  • Subsequent increases: increase in increments of 100 mg or less, once or twice weekly (2.2).
  • Maximum daily dose: 900 mg (2.2).
  • Administer orally using syringe provided (2.3).
  • Shake bottle for 10 seconds prior to withdrawing suspension from bottle; use oral syringes and syringe adaptor provided (2.3).

2.1 Required Laboratory Testing Prior to Initiation and During Therapy

Prior to initiating treatment with Clopaz, a baseline ANC must be obtained. The baseline ANC must be at least 1500/µL for the general population, and at least 1000/µL for patients with documented Benign Ethnic Neutropenia (BEN). To continue treatment, the ANC must be monitored regularly .

2.2 Dosing Information

The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day by the end of 2 weeks. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of orthostatic hypotension, bradycardia, and syncope, it is necessary to use this low starting dose, gradual titration schedule, and divided dosages [see Warnings and Precautions (5.3) ].

2.3 Important Administration Instructions

Clopaz Oral Suspension is administered to the mouth by the oral syringes provided (1 mL or 9 mL). After shaking the bottle for 10 seconds prior to each use, the syringe adaptor is pressed on top of the bottle. The oral syringe (1 mL or 9 mL) is filled with air, and inserted into the adaptor. The air is dispelled into the bottle and then the bottle is turned upside down. The prescribed amount of the suspension is drawn from the bottle and dispensed directly to the mouth. The prescribed dose should be administered immediately after it is prepared. Do not draw a dose and store it in the syringe for later use. After use, the oral syringe may be washed with warm water and dried for next use. The bottle may be closed with the same cap without removing the bottle adaptor. Educate patients and caregivers on the steps to administer Clopaz as described in the Patient Instructions for Use.

Clopaz can be taken with or without food .

2.4 Maintenance Treatment

Generally, patients responding to Clopaz should continue maintenance treatment on their effective dose beyond the acute episode.

2.5 Discontinuation of Treatment

Method of treatment discontinuation will vary depending on the patient's last ANC:

  • See Tables 2 or 3 for appropriate ANC monitoring based on the level of neutropenia if abrupt treatment discontinuation is necessary because of moderate to severe neutropenia.
  • Reduce the dose gradually over a period of 1 to 2 weeks if termination of Clopaz therapy is planned and there is no evidence of moderate to severe neutropenia.
  • For abrupt Clopaz discontinuation for a reason unrelated to neutropenia, continuation of the existing ANC monitoring is recommended for general population patients until their ANC is ≥1500/µL and for BEN patients until their ANC is ≥1000/µL or above their baseline.
  • Additional ANC monitoring is required for any patient reporting onset of fever during the 2 weeks after discontinuation [see Warnings and Precautions (5.1) ].
  • Monitor all patients carefully for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting, and diarrhea.

2.6 Re-Initiation of Treatment

When restarting Clopaz in patients who have discontinued Clopaz (i.e., 2 days or more since the last dose), re-initiate with 12.5 mg once daily or twice daily. This is necessary to minimize the risk of hypotension, bradycardia, and syncope . If that dose is well tolerated, the dose may be increased to the previously therapeutic dose more quickly than recommended for initial treatment.

2.7 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers

Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors ; moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John’s wort, and rifampin); or CYP1A2 inducers (e.g., tobacco smoking) (Table 1) .

Table 1: Dose Adjustment in Patients Taking Concomitant Medications


Co-medications


Scenarios


Initiating Clopaz while taking a co-medication


Adding a co-medication while taking Clopaz


Discontinuing a co-medication while continuing Clopaz


Strong CYP1A2 Inhibitors


Use one third of the Clopaz dose.


Increase Clopaz dose based on clinical response.


Moderate or Weak CYP1A2 Inhibitors


Monitor for adverse reactions. Consider reducing the Clopaz dose if necessary.


Monitor for lack of effectiveness. Consider increasing Clopaz dose if necessary.


CYP2D6 or CYP3A4 Inhibitors


Strong CYP3A4 Inducers


Concomitant use is not recommended. However, if the inducer is necessary, it may be necessary to increase the Clopaz dose. Monitor for decreased effectiveness.


Reduce Clopaz dose based on clinical response.


Moderate or weak CYP1A2 or CYP3A4 Inducers


Monitor for decreased effectiveness. Consider increasing the Clopaz dose if necessary.


Monitor for adverse reactions. Consider reducing the Clopaz dose if necessary.

2.8 Renal or Hepatic Impairment, or CYP2D6 Poor Metabolizers

It may be necessary to reduce the Clopaz dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers [see Use in Specific Populations (8.6, 8.7) ].

advertisement

3 DOSAGE FORMS AND STRENGTHS

Clopaz is available as a free-flowing yellow oral suspension. Each mL contains 50 mg of Clopaz.

  • Oral suspension: 50 mg per mL (3).

4 CONTRAINDICATIONS

  • Known hypersensitivity to Clopaz or any other component of Clopaz.

4.1 Hypersensitivity

Clopaz is contraindicated in patients with a history of serious hypersensitivity to Clopaz (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of Clopaz .

5 WARNINGS AND PRECAUTIONS

  • Eosinophilia: Assess for organ involvement. Discontinue if these occur (5.8).
  • QT Interval Prolongation: Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs) (5.9).
  • Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include:
    • Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes (5.10).
    • Dyslipidemia: Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics (5.10).
    • Weight Gain: Significant weight gain has occurred. Monitor weight gain (5.10).
  • Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and monitor closely. Assess for co-morbid conditions (5.11).
  • Hepatotoxicity: Can be fatal. Monitor for hepatotoxicity. Discontinue treatment if hepatitis or transaminase elevations combined with other symptoms occur (5.12).
  • Fever: Evaluate for infection, and for neutropenia, NMS (5.13).
  • Pulmonary Embolism (PE): Consider PE if respiratory distress, chest, pain, or deep vein thrombosis occurs (5.14).
  • Anticholinergic Toxicity: Use cautiously in presence of specific conditions (e.g., narrow angle glaucoma, use of anticholinergic drugs) (5.15).
  • Interference with Cognitive and Motor Performance: Advise caution when operating machinery, including automobiles (5.16).

5.1 Severe Neutropenia

Background

Clopaz can cause neutropenia (a low absolute neutrophil count [ANC]), defined as a reduction below pre-treatment normal levels of blood neutrophils. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced neutropenia than is the white blood cell (WBC) count. The ANC may also be calculated using the following formula: ANC equals the Total WBC count multiplied by the total percentage of neutrophils obtained from the differential (neutrophil “segs” plus neutrophil “bands”). Other granulocytes (basophils and eosinophils) contribute minimally to neutropenia and their measurement is not necessary [see Adverse Reactions (6.2) ]. Neutropenia may be mild, moderate, or severe. To improve and standardize understanding, “severe neutropenia” replaces the previous terms severe leukopenia, severe granulocytopenia, or agranulocytosis.

Severe neutropenia, ANC less than (<) 500/µL, occurs in a small percentage of patients taking Clopaz and is associated with an increase in the risk of serious and potentially fatal infections. Risk of neutropenia appears greatest during the first 18 weeks on treatment and then declines. The mechanism by which Clopaz causes neutropenia is unknown and is not dose-dependent.

Two separate management algorithms are provided below, the first for patients in the general population, and the second for patients identified to have baseline neutropenia.

Clopaz Treatment and Monitoring in the General Patient Population

Obtain a CBC, including the ANC value, prior to initiating treatment with Clopaz to ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/µL) and to permit later comparisons. Patients in the general population with an ANC equal to or greater than (≥) 1500/µL are considered within normal range (Table 2) and are eligible to initiate treatment. Weekly ANC monitoring is required for all patients during the first 6 months of treatment. If a patient's ANC remains equal to or greater than 1500/µL for the first 6 months of treatment, monitoring frequency may be reduced to every 2 weeks for the next 6 months. If the ANC remains equal to or greater than 1500/µL for the second 6 months of continuous therapy, ANC monitoring frequency may be reduced to once every 4 weeks thereafter.

Table 2: Clopaz Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring for the General Patient Population

ANC Level Clopaz

Treatment Recommendations

ANC Monitoring

Normal range

(≥1500/µL)

  • Initiate treatment
  • If treatment interrupted:
    • <30 days, continue monitoring as before
    • ≥30 days, monitor as if new patient
  • Weekly from initiation to 6 months
  • Every 2 weeks from 6 to 12 months
  • Monthly after 12 months
  • Discontinuation for reasons other than neutropenia
  • See Section 2.4

Mild Neutropenia (1000 to 1499/µL)*

  • Continue treatment
  • Three times weekly until ANC ≥1500/µL
  • Once ANC ≥1500/µL, return to patient's last “Normal Range” ANC monitoring interval**

Moderate Neutropenia (500 to 999/µL)*

  • Recommend hematology consultation
  • Interrupt treatment for suspected clozapine-induced neutropenia
  • Resume treatment once ANC ≥1000/µL
  • Daily until ANC ≥1000/µL, then
  • Three times weekly until ANC ≥1500/µL
  • Once ANC ≥1500/µL, check ANC weekly for 4 weeks, then return to patient's last “Normal Range” ANC monitoring interval**

Severe Neutropenia (less than 500/µL)*

  • Recommend hematology consultation
  • Interrupt treatment for suspected clozapine-induced neutropenia
  • Do not rechallenge unless prescriber determines benefits outweigh risks
  • Daily until ANC ≥1000/µL, then
  • Three times weekly until ANC ≥1500/µL
  • If patient rechallenged, resume treatment as a new patient under “Normal Range” monitoring once ANC ≥1500/µL

* Confirm all initial reports of ANC less than 1500/µL with a repeat ANC measurement within 24 hours

** If clinically appropriate

Clopaz Treatment and Monitoring in Patients with Benign Ethnic Neutropenia

Benign ethnic neutropenia (BEN) is a condition observed in certain ethnic groups whose average ANC values are lower than “standard” laboratory ranges for neutrophils. It is most commonly observed in individuals of African descent (approximate prevalence of 25-50%), some Middle Eastern ethnic groups, and in other non-Caucasian ethnic groups with darker skin. BEN is more common in men. Patients with BEN have normal hematopoietic stem-cell number and myeloid maturation, are healthy, and do not suffer from repeated or severe infections. They are not at increased risk for developing VERSACLOZ-induced neutropenia. Additional evaluation may be needed to determine if baseline neutropenia is due to BEN. Consider hematology consultation before initiating or during Clopaz treatment as necessary.

Patients with BEN require a different ANC algorithm for Clopaz management due to their lower baseline ANC levels. Table 3 provides guidelines for managing Clopaz treatment and ANC monitoring in patients with BEN.

Table 3: Patients with Benign Ethnic Neutropenia (BEN); Clopaz Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring

ANC Level Treatment Recommendations ANC Monitoring

Normal BEN Range

(Established ANC baseline ≥1000/µL)

  • Obtain at least two baseline ANC levels before initiating treatment
  • If treatment interrupted:
    • <30 days, continue monitoring as before
    • ≥30 days, monitor as if new patient
  • Weekly from initiation to 6 months
  • Every 2 weeks from 6 to 12 months
  • Monthly after 12 months
  • Discontinuation of treatment for reasons other than neutropenia
  • See Section 2.4

BEN Neutropenia (500 to 999/µL)*

  • Recommend hematology consultation
  • Continue treatment
  • Three times weekly until ANC ≥1000/µL or ≥patient's known baseline
  • Once ANC ≥1000/µL or at patient's known baseline, check ANC weekly for 4 weeks, then return to patient's last “Normal BEN Range” ANC monitoring interval**

BEN

Severe Neutropenia (less than 500/µL)*

  • Recommend hematology consultation
  • Interrupt treatment for suspected clozapine-induced neutropenia
  • Do not rechallenge unless prescriber determines benefits outweigh risks
  • Daily until ANC ≥500/µL, then
  • Three times weekly until ANC ≥patient's baseline
  • If patient rechallenged, resume treatment as a new patient under “Normal Range” monitoring once ANC ≥1000/µL or at patient's baseline

* Confirm all initial reports of ANC less than 1500/µL with a repeat ANC measurement within 24 hours

** If clinically appropriate

General Guidelines for Management of All Patients with Fever or with Neutropenia

  • Fever: Interrupt Clopaz as a precautionary measure in any patient who develops fever, defined as a temperature of 38.5°C [101.3°F] or greater, and obtain an ANC level. Fever is often the first sign of neutropenic infection.
  • ANC less than 1000/µL: If fever occurs in any patient with an ANC less than 1000/µL, initiate appropriate workup and treatment for infection and refer to Tables 2 or 3 for management.
  • Consider hematology consultation.
  • See Neuroleptic Malignant Syndrome (NMS) and Fever under WARNINGS AND PRECAUTIONS (5) and Instructions for Patients, under PATIENT COUNSELING INFORMATION (17).

Rechallenge after an ANC less than 500/µL (severe neutropenia)

For some patients who experience severe VERSACLOZ-related neutropenia, the risk of serious psychiatric illness from discontinuing Clopaz treatment may be greater than the risk of rechallenge (e.g., patients with severe schizophrenic illness who have no treatment options other than Clopaz). A hematology consultation may be useful in deciding to rechallenge a patient. In general, however, do not rechallenge patients who develop severe neutropenia with Clopaz or a Clopaz product.

If a patient will be rechallenged, the clinician should consider thresholds provided in Tables 2 and 3, the patient's medical and psychiatric history, a discussion with the patient and his/her caregiver about the benefits and risks of Clopaz rechallenge, and the severity and characteristics of the neutropenic episode.

Using Clopaz with Other Drugs Associated with Neutropenia

It is unclear if concurrent use of other drugs known to cause neutropenia increases the risk or severity of VERSACLOZ-induced neutropenia. There is no strong scientific rationale to avoid Clopaz treatment in patients concurrently treated with these drugs. If Clopaz is used concurrently with an agent known to cause neutropenia (e.g., some chemotherapeutic agents), consider monitoring patients more closely than the treatment guidelines provided in Tables 2 and 3. Consult with the treating oncologist in patients receiving concomitant chemotherapy.

5.2 Clopaz REMS Program

Clopaz is only available through a restricted program under a REMS called the Clopaz REMS Program because of the risk of severe neutropenia.

Notable requirements of the Clopaz REMS Program include:

  • Healthcare professionals who prescribe Clopaz must be certified with the program by enrolling and completing training.
  • Patients who receive Clopaz must be enrolled in the program and comply with the ANC testing and monitoring requirements.
  • Pharmacies dispensing Clopaz must be certified with the program by enrolling and completing training and must only dispense to patients who are eligible to receive Clopaz.

Further information is available at www.clozapinerems.com or 1-844-267-8678.

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

Hypotension, bradycardia, syncope, and cardiac arrest have occurred with Clopaz treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally mediated reflex bradycardia.

Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions . Consider reducing the dose if hypotension occurs. When restarting patients who have had even a brief interval off Clopaz (i.e., 2 days or more since the last dose), re-initiate treatment at 12.5 mg once daily or twice daily .

Use Clopaz cautiously in patients with cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (e.g., concomitant use of antihypertensives, dehydration and hypovolemia).

5.4 Falls

Clopaz may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic treatment.

5.5 Seizures

Seizure has been estimated to occur in association with Clopaz use at a cumulative incidence at one year of approximately 5%, based on the occurrence of one or more seizures in 61 of 1743 patients exposed to Clopaz during its clinical testing prior to domestic marketing. The risk of seizure is dose-related. Initiate treatment with a low dose (12.5 mg), titrate slowly, and use divided dosing.

Use caution when administering Clopaz to patients with a history of seizures or other predisposing risk factors for seizure (e.g., head trauma or other CNS pathology, use of medications that lower the seizure threshold, or alcohol abuse). Because of the substantial risk of seizure associated with Clopaz use, caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others (e.g., driving an automobile, operating complex machinery, swimming, climbing).

5.6 Myocarditis and Cardiomyopathy

Myocarditis and cardiomyopathy have occurred with the use of Clopaz. These reactions can be fatal. Discontinue Clopaz and obtain a cardiac evaluation upon suspicion of myocarditis or cardiomyopathy. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with Clopaz. However, if the benefit of Clopaz treatment is judged to outweigh the potential risks of recurrent myocarditis or cardiomyopathy, the clinician may consider rechallenge with Clopaz in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring.

Consider the possibility of myocarditis or cardiomyopathy in patients receiving Clopaz who present with chest pain, dyspnea, persistent tachycardia at rest, palpitations, fever, flu-like symptoms, hypotension, other signs or symptoms of heart failure, or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression). Myocarditis most frequently presents within the first two months of Clopaz treatment. Symptoms of cardiomyopathy generally occur later than clozapine-associated myocarditis and usually after 8 weeks of treatment. However, myocarditis and cardiomyopathy can occur at any period during treatment with Clopaz. It is common for nonspecific flu-like symptoms such as malaise, myalgia, pleuritic chest pain, and low-grade fevers to precede more overt signs of heart failure. Typical laboratory findings include elevated troponin I or T, elevated creatinine kinase-MB, peripheral eosinophilia, and elevated C-reactive protein (CRP). Chest roentgenogram may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionucleotide studies, or cardiac catheterization) may reveal evidence of left ventricular dysfunction.

5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in this population. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Clopaz is not approved for the treatment of patients with dementia-related psychosis .

5.8 Eosinophilia

Eosinophilia, defined as a blood eosinophil count of greater than 700/μL, has occurred with Clopaz treatment. In clinical trials, approximately 1% of patients developed eosinophilia. Clozapine-related eosinophilia usually occurs during the first month of treatment. In some patients, it has been associated with myocarditis, pancreatitis, hepatitis, colitis, and nephritis. Such organ involvement could be consistent with a drug reaction with eosinophilia and systemic symptoms syndrome (DRESS), also known as drug induced hypersensitivity syndrome (DIHS). If eosinophilia develops during Clopaz treatment, evaluate promptly for signs and symptoms of systemic reactions, such as rash or other allergic symptoms, myocarditis, or other organ-specific disease associated with eosinophilia. If clozapine-related systemic disease is suspected, discontinue Clopaz immediately.

If a cause of eosinophilia unrelated to Clopaz is identified (e.g., asthma, allergies, collagen vascular disease, parasitic infections, and specific neoplasms), treat the underlying cause and continue Clopaz.

Clozapine-related eosinophilia has also occurred in the absence of organ involvement and can resolve without intervention. There are reports of successful rechallenge after discontinuation of Clopaz, without recurrence of eosinophilia. In the absence of organ involvement, continue Clopaz under careful monitoring. If the total eosinophil count continues to increase over several weeks in the absence of systemic disease, the decision to interrupt Clopaz therapy and rechallenge after the eosinophil count decreases should be based on the overall clinical assessment, in consultation with an internist or hematologist.

5.9 QT Interval Prolongation

QT prolongation, Torsades de Pointes and other life-threatening ventricular arrhythmias, cardiac arrest, and sudden death have occurred with Clopaz treatment. When prescribing Clopaz, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of long QT syndrome or sudden cardiac death, significant cardiac arrhythmia, recent myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of Clopaz, and electrolyte abnormalities.

Prior to initiating treatment with Clopaz, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue Clopaz if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with Torsades de Pointes or other arrhythmias,, obtain a cardiac evaluation and discontinue Clopaz.

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of Clopaz. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmic (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Clopaz is primarily metabolized by CYP isoenzymes 1A2, 2D6, and 3A4. Concomitant treatment with inhibitors of these enzymes can increase the concentration of Clopaz .

Hypokalemia and hypomagnesemia increase the risk of QT prolongation. Hypokalemia can result from diuretic therapy, diarrhea, and other causes. Use caution when treating patients at risk for significant electrolyte disturbance, particularly hypokalemia. Obtain baseline measurements of serum potassium and magnesium levels, and periodically monitor electrolytes. Correct electrolyte abnormalities before initiating treatment with Clopaz.

5.10 Metabolic Changes

Atypical antipsychotic drugs, including Clopaz, have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including Clopaz. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on Clopaz should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

In a pooled data analysis of 8 studies in adult subjects with schizophrenia, the mean changes in fasting glucose concentration in the Clopaz and chlorpromazine groups were +11 mg/dL and +4 mg/dL respectively. A higher proportion of the Clopaz group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group (Table 4). The Clopaz doses were 100-900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for Clopaz and chlorpromazine.

Table 4: Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with Schizophrenia


Laboratory Parameter


Category Change (at least once) from baseline


Treatment Arm


N


n (%)


Fasting Glucose


Normal

(<100 mg/dL)

to

High (≥126 mg/dL)


Clopaz


198


53 (27)


Chlorpromazine


135


14 (10)


Borderline

(100 to 125 mg/dL)

to

High (≥126 mg/dL)


Clopaz


57


24 (42)


Chlorpromazine


43


12 (28)


Dyslipidemia

Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including Clopaz. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using Clopaz, is recommended.

In a pooled data analysis of 10 studies in adult subjects with schizophrenia, Clopaz treatment was associated with increases in serum total cholesterol. No data were collected on LDL and HDL cholesterol. The mean increase in total cholesterol was 13 mg/dL in the Clopaz group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with schizophrenia, Clopaz treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the Clopaz group and 39 mg/dL (35%) in the chlorpromazine group (Table 5). In addition, Clopaz treatment was associated with categorical increases in serum total cholesterol and triglyceride, as illustrated in Table 6. The proportion of patients with categorical increases in total cholesterol or fasting triglyceride increased with the duration of exposure. The median duration of Clopaz and chlorpromazine exposure was 45 days and 38 days, respectively. The Clopaz dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily.

Table 5: Mean Changes in Total Cholesterol and Triglyceride Concentration in Studies in Adult Subjects with Schizophrenia


Treatment Arm


Baseline total cholesterol concentration (mg/dL)


Change from baseline mg/dL (%)


Clopaz (N=334)


184


+13 (7)


Chlorpromazine (N=185)


182


+15 (8)


Baseline triglyceride concentration (mg/dL)


Change from baseline mg/dL (%)


Clopaz (N=6)


130


+71 (54)


Chlorpromazine (N=7)


110


+39 (35)


Table 6: Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with Schizophrenia


Laboratory Parameter


Category Change (at least once) from Baseline


Treatment Arm


N


n (%)


Total Cholesterol

(random or fasting)


Increase by ≥40

mg/dL


Clopaz


334


111 (33)


Chlorpromazine


185


46 (25)


Normal (<200 mg/dL)

to

High (≥240 mg/dL)


Clopaz


222


18 (8)


Chlorpromazine


132


3 (2)


Borderline

(200 - 239 mg/dL) to

High (≥240 mg/dL)


Clopaz


79


30 (38)


Chlorpromazine


34


14 (41)


Triglycerides

(fasting)


Increase by ≥50 mg/dL


Clopaz


6


3 (50)


Chlorpromazine


7


3 (43)


Normal (<150 mg/dL)

to

High (≥200 mg/dL)


Clopaz


4


0 (0)


Chlorpromazine


6


2 (33)


Borderline

(≥150 mg/dL and

<200 mg/dL) to

High (≥200 mg/dL)


Clopaz


1


1 (100)


Chlorpromazine


1


0 (0)


Weight Gain

Weight gain has occurred with the use of antipsychotics, including Clopaz. Monitor weight during treatment with Clopaz. Table 7 summarizes the data on weight gain by the duration of exposure pooled from 11 studies with Clopaz and active comparators. The median duration of exposure was 609, 728, and 42 days, in the Clopaz, olanzapine, and chlorpromazine group, respectively.

Table 7: Mean Change in Body Weight (kg) by duration of exposure from studies in adult subjects with schizophrenia


Metabolic parameter


Exposure duration


Clopaz

(N=669)


Olanzapine

(N=442)


Chlorpromazine

(N=155)


n


Mean


n


Mean


n


Mean


Weight change from baseline


2 weeks (Day 11 – 17)


6


+0.9


3


+0.7


2


-0.5


4 weeks (Day 21 – 35)


23


+0.7


8


+0.8


17


+0.6


8 weeks (Day 49 – 63)


12


+1.9


13


+1.8


16


+0.9


12 weeks (Day 70 – 98)


17


+2.8


5


+3.1


0


0


24 weeks (154 – 182)


42


-0.6


12


+5.7


0


0


48 weeks (Day 322 – 350)


3


+3.7


3


+13.7


0


0


Table 8 summarizes pooled data from 11 studies in adult subjects with schizophrenia demonstrating weight gain ≥7% of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the Clopaz, olanzapine, and chlorpromazine group, respectively.

Table 8: Proportion of adult subjects in schizophrenia studies with weight gain ≥7% relative to baseline body weight


Weight change


Clopaz


Olanzapine


Chlorpromazine


N


669


442


155


≥7% (inclusive)


236 (35%)


203 (46%)


13 (8%)

5.11 Neuroleptic Malignant Syndrome

Antipsychotic drugs including Clopaz can cause a potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Associated findings can include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe neutropenia, infection, heat stroke, primary CNS pathology, central anticholinergic toxicity, extrapyramidal symptoms, and drug fever).

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of co-morbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.

NMS has occurred with Clopaz monotherapy and with concomitant CNS-active medications, including lithium.

5.12 Hepatotoxicity

Severe, life threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis have been reported in patients treated with Clopaz [see Adverse Reactions (6.2) ] . Monitor for the appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy. Perform serum tests for liver injury and consider permanently discontinuing treatment if hepatitis or transaminase elevations combined with other systemic symptoms are due to Clopaz.

5.13 Fever

During Clopaz therapy, patients have experienced transient, clozapine-related fever. The peak incidence is within the first 3 weeks of treatment. While this fever is generally benign and self-limited, it may necessitate discontinuing treatment. The fever can be associated with an increase or decrease in WBC count. Carefully evaluate patients with fever to rule out severe neutropenia or infection. Consider the possibility of NMS [see Warnings and Precautions ].

5.14 Pulmonary Embolism

Pulmonary embolism and deep vein thrombosis have occurred in patients treated with Clopaz. Consider the possibility of pulmonary embolism in patients who present with deep vein thrombosis, acute dyspnea, chest pain, or with other respiratory signs and symptoms. Whether pulmonary embolus and deep vein thrombosis can be attributed to Clopaz or some characteristic(s) of patients is not clear.

5.15 Anticholinergic Toxicity

Clopaz has potent anticholinergic effects. Treatment with Clopaz can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions.

Treatment with Clopaz can result in gastrointestinal adverse reactions, including constipation, intestinal obstruction, fecal impaction, and paralytic ileus. Such reactions can be fatal. Constipation should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.

5.16 Interference with Cognitive and Motor Performance

Clopaz can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that Clopaz does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.

5.17 Tardive Dyskinesia

Tardive dyskinesia has occurred in patients treated with antipsychotic drugs, including Clopaz. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe Clopaz in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration necessary to control symptoms. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with Clopaz despite the presence of the syndrome.

There is no known treatment for TD. However, the syndrome may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.

5.18 Cerebrovascular Adverse Reactions

In controlled trials, elderly patients with dementia-related psychosis treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for Clopaz or other antipsychotics or other patient populations. Clopaz should be used with caution in patients with risk factors for cerebrovascular adverse reactions.

5.19 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of Clopaz

If abrupt discontinuation of Clopaz is necessary (because of severe neutropenia or another medical condition, for example) , monitor carefully for the recurrence of psychotic symptoms and adverse reactions related to cholinergic rebound, such as profuse sweating, headache, nausea, vomiting and diarrhea.

advertisement

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

  • Severe Neutropenia .
  • Orthostatic Hypotension, Bradycardia, and Syncope .
  • Falls
  • Seizures [see Warnings and Precautions (5.5) ].
  • Myocarditis and Cardiomyopathy [see Warnings and Precautions (5.6) ].
  • Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.7) ].
  • Eosinophilia [see Warnings and Precautions (5.8) ].
  • QT Interval Prolongation [see Warnings and Precautions (5.9) ].
  • Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.10) ].
  • Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.11) ].
  • Hepatotoxicity .
  • Fever [see Warnings and Precautions (5.13) ].
  • Pulmonary Embolism [see Warnings and Precautions (5.14) ].
  • Anticholinergic Toxicity [see Warnings and Precautions (5.15) ].
  • Interference with Cognitive and Motor Performance [see Warnings and Precautions (5.16) ].
  • Tardive Dyskinesia [see Warnings and Precautions (5.17) ].
  • Cerebrovascular Adverse Reactions [see Warnings and Precautions (5.18) ].
  • Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation [see Warnings and Precautions (5.19) ].

Most common adverse reactions (≥5%) were: CNS reactions (sedation, dizziness/vertigo, headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions (constipation and nausea); and fever (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals, at 1-800-520-5568 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions (>5%) across Clopaz clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hypersalivation, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. Table 9 summarizes the most commonly reported adverse reactions (>5%) in clozapine-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant schizophrenia.

Table 9: Common Adverse Reactions (≥5%) in the 6-Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant Schizophrenia


Adverse Reaction


Clopaz

(N=126)

(%)


Chlorpromazine

(N=142)

(%)


Sedation

Tachycardia

Constipation

Dizziness

Hypotension

Fever (hyperthermia)

Hypersalivation

Hypertension

Headache

Nausea/vomiting

Dry mouth


21

17

16

14

13

13

13

12

10

10

5


13

11

12

16

38

4

1

5

10

12

20


Table 10 summarizes the adverse reactions reported in clozapine-treated patients at a frequency of 2% or greater across all Clopaz studies (excluding the 2-year InterSePT Study). These rates are not adjusted for duration of exposure.

Table 10: Adverse Reactions (≥2%) Reported in Clozapine-treated Patients (N=842) across all Clopaz Studies (excluding the 2-year InterSePT Study)


Body System

Adverse Reaction


Clopaz

N=842

Percentage of Patients


Central Nervous System

Drowsiness/Sedation

Dizziness/Vertigo

Headache

Tremor


39

19

7

6


Syncope

Disturbed Sleep/Nightmares

Restlessness

Hypokinesia/Akinesia


6

4

4

4


Agitation

Seizures (convulsions)

Rigidity

Akathisia

Confusion

Fatigue

Insomnia


4

3†

3

3

3

2

2


Cardiovascular

Tachycardia

Hypotension

Hypertension


25†

9

4


Gastrointestinal

Constipation

Nausea

Abdominal Discomfort/Heartburn

Nausea/Vomiting

Vomiting

Diarrhea


14

5

4

3

3

2


Urogenital

Urinary Abnormalities


2


Autonomic Nervous System

Salivation

Sweating

Dry Mouth

Visual Disturbances


31

6

6

5


Skin

Rash


2


Hemic/Lymphatic

Leukopenia/Decreased WBC/Neutropenia


3


Miscellaneous

Fever

Weight Gain


5

4

  • † Rate based on population of approximately 1700 exposed during premarket clinical evaluation of Clopaz.

Table 11 summarizes the most commonly reported adverse reactions (>10% of the Clopaz or olanzapine group) in the InterSePT Study. This was an adequate and well-controlled, two-year study evaluating the efficacy of Clopaz relative to olanzapine in reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. The rates are not adjusted for duration of exposure.

Table 11: Incidence of Adverse Reactions in Patients Treated with Clopaz or Olanzapine in the InterSePT Study (≥10% in the Clopaz or olanzapine group)


Adverse Reactions


Clopaz

N=479

% Reporting


Olanzapine

N=477

% Reporting


Salivary hypersecretion


48%


6%


Somnolence


46%


25%


Weight increased


31%


56%


Dizziness (excluding vertigo)


27%


12%


Constipation


25%


10%


Insomnia


20%


33%


Nausea


17%


10%


Vomiting


17%


9%


Dyspepsia


14%


8%


Dystonia

Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Clopaz. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Central Nervous System

Delirium, EEG abnormal, myoclonus, paresthesia, possible cataplexy, status epilepticus, obsessive compulsive symptoms, and post-discontinuation cholinergic rebound adverse reactions.

Cardiovascular System

Atrial or ventricular fibrillation, ventricular tachycardia, QT interval prolongation, Torsades de Pointes, myocardial infarction, cardiac arrest, and periorbital edema.

Endocrine System

Pseudopheochromocytoma.

Gastrointestinal System

Acute pancreatitis, dysphagia, salivary gland swelling.

Hepatobiliary System

Cholestasis, hepatitis, jaundice, hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure.

Immune System Disorders

Angioedema, leukocytoclastic vasculitis.

Urogenital System

Acute interstitial nephritis, nocturnal enuresis, priapism, and renal failure.

Skin and Subcutaneous Tissue Disorders

Hypersensitivity reactions: photosensitivity, vasculitis, erythema multiforme, skin pigmentation disorder, and Stevens-Johnson Syndrome.

Musculoskeletal System and Connective Tissue Disorders

Myasthenic syndrome, rhabdomyolysis, and systemic lupus erythematosus.

Respiratory System

Aspiration, pleural effusion, pneumonia, lower respiratory tract infection.

Hemic and Lymphatic System

Mild, moderate, or severe leukopenia, agranulocytosis, granulocytopenia, WBC decreased, deep vein thrombosis, elevated hemoglobin/hematocrit, erythrocyte sedimentation rate (ESR) increased, sepsis, thrombocytosis, and thrombocytopenia.

Vision Disorders

Narrow-angle glaucoma.

Miscellaneous

Creatine phosphokinase elevation, hyperuricemia, hyponatremia, and weight loss.

advertisement

7 DRUG INTERACTIONS

  • Concomitant use of Strong CYP1A2 Inhibitors: Reduce Clopaz dose to one third when coadministered with strong CYP1A2 inhibitors (2.7, 7.1).
  • Concomitant use of Strong CYP3A4 Inducers is not recommended (2.7, 7.1).
  • Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing Clopaz dose when CYP1A2 (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued (2.7, 7.1).

7.1 Potential for Other Drugs to Affect Clopaz

Clopaz is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering Clopaz concomitantly with drugs that are inducers or inhibitors of these enzymes.

CYP1A2 Inhibitors

Concomitant use of Clopaz and CYP1A2 inhibitors can increase plasma levels of Clopaz, potentially resulting in adverse reactions. Reduce the Clopaz dose to one third of the original dose when Clopaz is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The Clopaz dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued .

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when Clopaz is coadministered with these inhibitors. Consider reducing the Clopaz dosage if necessary .

CYP2D6 and CYP3A4 Inhibitors

Concomitant treatment with Clopaz and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase Clopaz levels and lead to adverse reactions . Use caution and monitor patients closely when using such inhibitors. Consider reducing the Clopaz dose .

CYP1A2 and CYP3A4 Inducers

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of Clopaz, resulting in decreased effectiveness of Clopaz. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John’s wort, and rifampin. It may be necessary to increase the Clopaz dose if used concomitantly with inducers of these enzymes. However, concomitant use of Clopaz and strong CYP3A4 inducers is not recommended .

Consider reducing the Clopaz dosage when discontinuing coadministered enzyme inducers, because discontinuation of inducers can result in increased Clopaz plasma levels and an increased risk of adverse reactions .

Drugs that Cause QT Interval Prolongation

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of Clopaz. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus) [see Warnings and Precautions (5.9) ].

7.2 Potential for Clopaz to Affect Other Drugs

Concomitant use of Clopaz with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering Clopaz with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).

8 USE IN SPECIFIC POPULATIONS

  • Nursing Mothers: Discontinue drug or discontinue nursing, taking into consideration importance of drug to mother.

8.1 Pregnancy

Pregnancy Category B

Risk Summary

There are no adequate or well-controlled studies of Clopaz in pregnant women.

Reproduction studies have been performed in rats and rabbits at doses up to 0.4 and 0.9 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m2 body surface area basis. The studies revealed no evidence of impaired fertility or harm to the fetus due to Clopaz. Because animal reproduction studies are not always predictive of human response, Clopaz should be used during pregnancy only if clearly needed.

Clinical Considerations

Consider the risk of exacerbation of psychosis when discontinuing or changing treatment with antipsychotic medications during pregnancy and postpartum. Consider early screening for gestational diabetes for patients treated with antipsychotic medications [see Warnings and Precautions (5.10) ]. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Monitor neonates for symptoms of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulties. The severity of complications can vary from self-limited symptoms to some neonates requiring intensive care unit support and prolonged hospitalization.

Animal Data

In embryofetal developmental studies, Clopaz had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m2 body surface area basis.

In peri/postnatal developmental studies, pregnant female rats were administered Clopaz over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to reach sexual maturity and mated. Clopaz caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1 or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m2 body surface area basis.

8.3 Nursing Mothers

Clopaz is present in human milk. Because of the potential for serious adverse reactions in nursing infants from Clopaz, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

There have not been sufficient numbers of geriatric patients in clinical studies utilizing Clopaz to determine whether those over 65 years of age differ from younger subjects in their response to Clopaz.

Orthostatic hypotension and tachycardia can occur with Clopaz treatment . Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to these effects.

Elderly patients may be particularly susceptible to the anticholinergic effects of Clopaz, such as urinary retention and constipation [see Warnings and Precautions (5.15) ].

Carefully select Clopaz doses in elderly patients, taking into consideration their greater frequency of decreased hepatic, renal, or cardiac function, as well as other concomitant disease and other drug therapy. Clinical experience suggests that the prevalence of tardive dyskinesia appears to be highest among the elderly; especially elderly women [see Warnings and Precautions (5.17) ].

8.6 Patients with Renal or Hepatic Impairment

Dose reduction may be necessary in patients with significant impairment of renal or hepatic function. Clopaz concentrations may be increased in these patients, because Clopaz is almost completely metabolized and then excreted .

8.7 CYP2D6 Poor Metabolizers

Dose reduction may be necessary in patients who are CYP2D6 poor metabolizers. Clopaz concentrations may be increased in these patients, because Clopaz is almost completely metabolized and then excreted .

8.8 Hospice Patients

For hospice patients (i.e., terminally ill patients with an estimated life expectancy of 6 months or less), the prescriber may reduce the ANC monitoring frequency to once every 6 months, after a discussion with the patient and his/her caregiver. Individual treatment decisions should weigh the importance of monitoring ANC in the context of the need to control psychiatric symptoms and the patient's terminal illness.

10 OVERDOSAGE

10.1 Overdosage Experience

The most commonly reported signs and symptoms associated with Clopaz overdose are: sedation, delirium, coma, tachycardia, hypotension, respiratory depression or failure, and hypersalivation. There are reports of aspiration pneumonia, cardiac arrhythmias, and seizure. Fatal overdoses have been reported with Clopaz, generally at doses above 2500 mg. There have also been reports of patients recovering from overdoses well in excess of 4 g.

10.2 Management of Overdosage

For the most up-to-date information on the management of Clopaz overdosage, contact a certified Regional Poison Control Center (1-800-222-1222). Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians’ Desk Reference® , a registered trademark of PDR Network. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. There are no specific antidotes for Clopaz.

In managing overdosage, consider the possibility of multiple-drug involvement.

11 DESCRIPTION

Clopaz, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine.

The structural formula is:

Clopaz is available as a free-flowing yellow suspension. Each mL contains 50 mg of Clopaz.

The active component of Clopaz is Clopaz. The remaining components are glycerin, sorbitol (non-crystallizing), sodium dihydrogen phosphate dihydrate, xanthan gum, sodium methylparaben, sodium propylparaben, povidone, water, and sodium hydroxide to adjust to a pH range of 6.5 – 7.0.

Description: 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of Clopaz is unknown. However, it has been proposed that the therapeutic efficacy of Clopaz in schizophrenia is mediated through antagonism of the dopamine type 2 and the serotonin type 2A (5-HT2A) receptors. Clopaz also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.

12.2 Pharmacodynamics

Clopaz demonstrated binding affinity to the following receptors: histamine H1 (Ki 1.1 nM), adrenergic α1A (Ki 1.6 nM), serotonin 5-HT6 (Ki 4 nM), serotonin 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), serotonin 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), dopamine D4 (Ki 24 nM), adrenergic α2A (Ki 90 nM), serotonin 5-HT3 (Ki 95 nM), serotonin 5-HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and dopamine D3 (Ki 555 nM).

Clopaz causes little or no prolactin elevation.

Clinical electroencephalogram (EEG) studies demonstrated that Clopaz increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during Clopaz therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep.

12.3 Pharmacokinetics

Absorption

In man, Clopaz tablets (25 mg and 100 mg) are equally bioavailable relative to a Clopaz solution. Clopaz Oral Suspension is bioequivalent to Clopaz marketed tablets.

Following oral administration of 100 mg to 800 mg Clopaz, once daily, the average steady-state peak plasma concentration was 275 ng/mL (range: 105 - 723 ng/mL), occurring at the average of 2.2 hours (range: 1 - 3.5 hours) after dosing. The average minimum concentration at steady-state was 75 ng/mL (range: 11 - 198 ng/mL).

When Clopaz was administered after a high fat meal there was no effect on the AUCss or Cmin, ss, however Cmax was reduced about 20%, and there was a slight delay in Tmax of 0.5 hour from a median Tmax of 2.0 hours under fasted conditions to 2.5 hours under fed conditions. The decrease in Cmax is not considered clinically relevant. Therefore Clopaz may be taken without regard to meals.

Distribution

Clopaz is approximately 97% bound to serum proteins. The interaction between Clopaz and other highly protein-bound drugs has not been fully evaluated but may be important .

Metabolism and Excretion

Clopaz is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. Clopaz is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The demethylated, hydroxylated, and N-oxide derivatives are components in both urine and feces. Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and N-oxide derivatives were inactive. The mean elimination half-life of Clopaz after a single 75 mg dose was 8 hours (range: 4-12 hours), compared to a mean elimination half-life of 12 hours (range: 4-66 hours), after achieving steady-state with 100 mg twice daily dosing.

A comparison of single-dose and multiple-dose administration of Clopaz demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady-state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum Clopaz plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.

Drug-Drug Interaction Studies

Fluvoxamine

A pharmacokinetic study was conducted in 16 schizophrenic patients who received Clopaz under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of Clopaz and its metabolites, N-desmethylclozapine and Clopaz N-oxide, were elevated about three-fold compared to baseline steady-state concentrations.

Paroxetine, Fluoxetine, and Sertraline

In a study of schizophrenic patients (n=14) who received Clopaz under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of Clopaz and its metabolites. However, other published reports describe modest elevations (less than two-fold) of Clopaz and metabolite concentrations when Clopaz was taken with paroxetine, fluoxetine, and sertraline.

Specific Population Studies

Renal or Hepatic Impairment

No specific pharmacokinetic studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of Clopaz. Higher Clopaz plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses.

CYP2D6 Poor Metabolizers

A subset (3%–10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of Clopaz when given usual doses.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m2 body surface area basis.

Mutagenesis

Clopaz was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the in vitro mammalian V79 in Chinese hamster cells, the in vitro unscheduled DNA synthesis in rat hepatocytes, or the in vivo micronucleus assay in mice.

Impairment of Fertility

Clopaz had no effect on any parameters of fertility, pregnancy, fetal weight, or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m2 body surface area basis.

14 CLINICAL STUDIES

14.1 Treatment-Resistant Schizophrenia

The efficacy of Clopaz in treatment-resistant schizophrenia was established in a multicenter, randomized, double-blind, active-controlled study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions – Severity Scale score of at least 4 (moderately ill).

In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6-week trial. Patients with an inadequate response to haloperidol (n=268) were randomized to double-blind treatment with Clopaz (N=126) or chlorpromazine (N=142). The maximum daily Clopaz dose was 900 mg; the mean daily dose was >600 mg). The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was >1200 mg.

The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of <3 (mildly ill), or (2) a BPRS score of <35, at the end of 6 weeks of treatment. Approximately 88% of patients from the Clopaz and chlorpromazine groups completed the 6-week trial. At the end of six weeks, 30% of the Clopaz group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p<0.001). The mean change in total BPRS score was -16 and -5 in the Clopaz and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the Clopaz and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the Clopaz and chlorpromazine group, respectively. These changes in the Clopaz group were statistically significantly greater than in the chlorpromazine group (p<0.001 in each analysis).

14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

The effectiveness of Clopaz in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT, a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of Clopaz (Clozaril®) versus olanzapine (Zyprexa®, a registered trademark of Eli Lilly and Company) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at risk for recurrent suicidal behavior. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met one of the following criteria:

  • They had attempted suicide within the three years prior to their baseline evaluation.
  • They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
  • They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
  • They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.

Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200–900 mg/day for Clopaz and 5–20 mg/day for olanzapine. For the 956 patients who received Clopaz or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group.

The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide; (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by “much worsening” or “very much worsening” from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the Suicide Monitoring Board (SMB), a group of experts blinded to patient data.

A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about one-fourth of the total patient population (27%) was identified as “treatment-resistant” at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range: 18–69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of “other” races.

Patients treated with Clopaz had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of Clopaz in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of Clopaz over olanzapine.

The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for Clopaz patients than for olanzapine patients at Week 104: Clopaz 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).

Figure 1. Cumulative Probability of a Significant Suicide Attempt or Hospitalization to Prevent Suicide in Patients with Schizophrenia or Schizoaffective Disorder at High Risk of Suicidality

Figure-02 Cumulative Probability

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Oral Suspension

Free-flowing, yellow suspension in amber bottle containing 100 mL. Each box contains 1 x 1 mL oral syringe, 1 x 9 mL oral syringe and 1 bottle adaptor.

NDC No. 18860-121-01

16.2 Storage and Handling

Store Clopaz at or below 25°C (77°F). Do not refrigerate or freeze. Protect from light. Shake well for 10 seconds before use.

The suspension is stable for 100 days after initial bottle opening.

Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

Discuss the following issues with patients and caregivers:

  • Severe Neutropenia
  • Instruct patients (and caregivers) beginning treatment with Clopaz about the risk of developing severe neutropenia and infection.
  • Instruct patients to immediately report to their physician any symptom or sign of infection (e.g., flu-like illness; fever; lethargy; general weakness or malaise; mucus membrane ulceration; skin, pharyngeal, vaginal, urinary, or pulmonary infection; or extreme weakness or lethargy) occurring at any time during Clopaz therapy, to aid in evaluation for neutropenia and to institute prompt and appropriate management [see Warnings and Precautions (5.1), (5.11) , and (5.13)].
  • Inform patients and caregivers Clopaz is available only through a restricted program called the Clopaz REMS Program designed to ensure the required blood monitoring, in order to reduce the risk of developing severe neutropenia. Advise patients and caregivers of the importance of having blood tested as follows:
    • Weekly blood tests are required for the first 6 months.
    • An ANC is required every 2 weeks for the next 6 months if an acceptable ANC is maintained during the first 6 months of continuous therapy.
    • An ANC is required once every 4 weeks thereafter if an acceptable ANC is maintained during the second 6 months of continuous therapy.
  • Clopaz is available only from certified pharmacies participating in the program. Provide patients (and caregivers) with website information and the telephone number on how to obtain the product.
  • Orthostatic Hypotension, Bradycardia, and Syncope: Inform patients and caregivers about the risk of orthostatic hypotension and syncope, especially during the period of initial dose titration. Instruct them to strictly follow the clinician’s instructions for dosage and administration. Advise patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of bradycardia or arrhythmia .
  • Falls: Inform patients of the risk of falls, which may lead to fractures or other injuries .
  • Seizures: Inform patients and caregivers about the significant risk of seizure during Clopaz treatment. Caution them about driving and any other potentially hazardous activity while taking Clopaz [see Warnings and Precautions (5.5) ].
  • QT Interval Prolongation: Advise patients to consult their clinician immediately if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia. Instruct patients to not take Clopaz with other drugs that cause QT interval prolongation. Instruct patients to inform their clinicians that they are taking Clopaz before any new drug [see Warnings and Precautions (5.9) and Drug Interactions (7.1)].
  • Metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain): Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include hyperglycemia and diabetes mellitus, dyslipidemia, weight gain, and cardiovascular reactions. Educate patients and caregivers about the symptoms of hyperglycemia (high blood sugar) and diabetes mellitus (e.g., polydipsia, polyuria, polyphagia, and weakness). Monitor all patients for these symptoms. Patients who are diagnosed with diabetes or have risk factors for diabetes (obesity, family history of diabetes) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of hyperglycemia should have assessments of fasting glucose. Clinical monitoring of weight is recommended [see Warnings and Precautions (5.10) ].
  • Interference with Cognitive and Motor Performance: Because Clopaz may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Clopaz therapy does not affect them adversely [see Warnings and Precautions (5.16) ].
  • Hepatotoxicity: Instruct patients to immediately report to their physician any symptoms or signs of potential liver injury (e.g. fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy) .
  • Missed Doses and Re-Initiating Treatment: Inform patients and caregivers that if the patient misses taking Clopaz for more than 2 days, they should not restart his or her medication at the same dosage but should contact their physician for dosing instructions .
  • Pregnancy: Patients and caregivers should notify the clinician if the patient becomes pregnant or intends to become pregnant during therapy .
  • Nursing: Advise patients and caregivers that the patient should not breast feed an infant if she is taking Clopaz .
  • Concomitant Medication: Advise patients to inform their health care provider if they are taking, or plan to take, any prescription or over-the-counter drugs; there is a potential for significant drug-drug interactions .
  • Patient Instructions for Use: Educate the patient and caregiver about the Patient Instructions for Use if Clopaz will be administered at home. Discuss the specific steps for administering the prescribed dose using the oral syringe .

Distributed by:

Jazz Pharmaceuticals, Inc.

Palo Alto, CA 94304

U.S. Patent No. 8057811

Clopaz® is a trademark of Jazz Pharmaceuticals plc or its subsidiaries.

Revised: February 2017

Patient Information

Clopaz® (VER sa kloz)

(clozapine)

Oral Suspension

Read this Patient Information before you start taking Clopaz and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about Clopaz?

Clopaz can cause serious side effects, including:

1. Severe neutropenia, a blood disorder that can lead to serious infections and death. Severe neutropenia means that you do not have enough of certain white blood cells to fight infection. Tell your healthcare provider right away if you have any of the following symptoms or signs of neutropenia or infection:

  • Skin, throat, urinary tract, vaginal, pneumonia, or any other infection
  • Fever or chills
  • Sores or ulcers inside your mouth, gums or on your skin
  • Wounds that take a long time to heal
  • Feel like you have the flu
  • Pain or burning while urinating
  • Unusual vaginal discharge or itching
  • Abdominal pain
  • Sores or pain in or around your rectal area
  • Feel extremely tired or weak

If you have symptoms of severe neutropenia or infection you will need to have a blood test right away to check if Clopaz is causing your symptoms. You must have frequent blood tests while taking Clopaz so your healthcare provider can make sure you are not getting severe neutropenia or infection.

Clopaz is available only through a restricted program called the Clopaz REMS Program. This program makes sure that you will receive each refill of Clopaz only if you have a blood test and your blood test result is acceptable to your healthcare provider.

During your first 6 months of Clopaz treatment, you will have weekly blood tests. If you have not taken Clopaz before, you will need weekly blood tests when you first start Clopaz. If you have acceptable blood test results during your first 6 months of Clopaz treatment, you can have a blood test every other week for the next 6 months. After a year of acceptable blood test results, you can have blood tests every 4 weeks while you are taking Clopaz.

2. Decreased blood pressure (orthostatic hypotension), slow heart rate (bradycardia), or fainting (syncope) that can lead to death. Lightheadedness or fainting caused by a sudden change in your heart rate and blood pressure when you rise too quickly from a sitting or lying position can happen while you take Clopaz and can be life threatening. These problems may happen more often when you are first starting treatment with Clopaz or when your dose is increased. Tell your healthcare provider right away if you feel faint, lose consciousness, or have symptoms of slow heart rate or an irregular heart rhythm.

3. Seizures. Seizures can occur during Clopaz treatment. Be especially careful while driving or during any other dangerous activity while taking Clopaz.

4. Myocarditis (heart muscle inflammation) and cardiomyopathy (heart muscle weakness) that may lead to death. Symptoms of myocarditis and cardiomyopathy include:

5. Higher risk of death in elderly people with memory loss (dementia) or psychosis. Clopaz can increase the risk of death in elderly people who have dementia. Clopaz is not for treating psychosis in elderly people with dementia.

What is Clopaz?

Clopaz is a prescription antipsychotic medicine used to treat people with certain types of schizophrenia, including people who:

  • are not helped by other schizophrenia medicines
  • have been suicidal and may be at risk of suicidal behavior again

It is not known if Clopaz is safe and effective in children.

Who should not take Clopaz?

Do not take Clopaz if you:

  • have blood problems called neutropenia
  • are allergic to Clopaz or any of the ingredients in Clopaz. See the end of this Patient Information Leaflet for a complete list of ingredients in Clopaz.

What should I tell my healthcare provider before taking Clopaz?

Before you take Clopaz, tell your healthcare provider about all of your medical conditions, including if you:

  • have or have had heart problems or a family history of heart problems including heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
  • have or have had liver or kidney problems
  • have or have had seizures or epilepsy
  • have or have had low levels of potassium or magnesium in your blood
  • have diabetes
  • have increased pressure in your eyes (glaucoma)
  • have had Neuroleptic Malignant Syndrome (NMS)
  • have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
  • have or have had diarrhea or constipation
  • have or have had an enlarged prostate gland
  • smoke tobacco
  • plan to stop smoking tobacco while taking Clopaz
  • use products containing caffeine
  • are pregnant or plan to become pregnant. It is not known if Clopaz will harm your unborn baby. Call your healthcare provider right away if you become pregnant while taking Clopaz.
  • are breastfeeding or plan to breastfeed. Clopaz can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take Clopaz. Do not breastfeed while taking Clopaz.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Clopaz and other medicines may affect each other causing side effects.

Especially tell your healthcare provider if you take:

  • chemotherapy, radiation, or other medicines that cause agranulocytosis, neutropenia, low white blood cell count, or affect your bone marrow
  • other antipsychotics or other medicines that can affect the amount of Clopaz in your blood
  • medicines used to treat anxiety, relax your muscles, or help you sleep
  • any medicines that make you feel sleepy
  • antibiotics
  • medicines used to treat heart problems
  • medicines used to lower the amount of water in your body (diuretics)
  • medicines used for birth control

Ask your healthcare provider for a list of these medicines if you are not sure.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take Clopaz?

  • Read the “Instructions for Use” at the end of this Patient Information for specific information about the right way to use Clopaz.
  • Your pharmacist should go over the instructions for how to use Clopaz with you when you receive your first prescription.
  • Take Clopaz exactly as your healthcare provider tells you to take it. Talk to your healthcare provider or pharmacist if you are not sure how to take Clopaz.
  • Do not change your dose or stop taking Clopaz without talking to your healthcare provider.

The symptoms of Clopaz overdose can include:

If you miss a dose of Clopaz for more than 2 days, check with your healthcare provider before starting to take it again to make sure you take the correct dose.

What should I avoid while taking Clopaz?

  • You should not drink alcohol while taking Clopaz. It can increase your chances of getting serious side effects.
  • Do not drive, operate machinery, swim, climb, or do other dangerous activities until you know how Clopaz affects you.

What are the possible side effects of Clopaz?

Clopaz may cause serious side effects, including:

  • See "What is the most important information I should know about Clopaz?"
  • high count of a certain white blood cell (eosinophilia)
  • problems with your heartbeat. These heart problems can cause death. Call your healthcare provider right away if you have any of these symptoms:
    • passing out or feeling like you will pass out
    • dizziness
    • feeling as if your heart is pounding or missing beats
  • high blood sugar (diabetes) and changes in the fat levels in your blood (dyslipidemia)
  • Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can happen in people who take Clopaz. NMS can cause death and must be treated in a hospital. Call your healthcare provider right away if you become severely ill and have any of these symptoms:
    • high fever
    • excessive sweating
    • stiff muscles
    • confusion
    • changes in your breathing, heartbeat and blood pressure
  • falls, which may lead to fractures or other injuries
  • liver problems. Call your healthcare provider right away if you have any of these symptoms:
    • nausea
    • vomiting
    • loss of appetite
    • feel tired
    • pain on the right side of your stomach (abdomen)
    • yellowing of your skin or the whites of your eyes
  • fever. Some people may have a fever that comes and goes while they take Clopaz. This happens more often in the first 3 weeks you take Clopaz. Talk to your healthcare provider if you have a fever.
  • blood clot in your lung (pulmonary embolism) or in the veins of your legs (deep-vein thrombosis). Get emergency help right away if you have symptoms of a blood clot including:
    • chest pain and shortness of breath
    • swelling or pain in your leg, ankle or foot
    • warm feeling in the skin of your affected leg
    • changes in your skin color such as turning pale or blue
  • a problem that includes dry mouth, increased sweating, increased pulse rate and constipation (anticholinergic toxicity)
  • problems thinking clearly and moving your body
  • uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
  • stroke in elderly people (cerebrovascular problems)

The most common side effects of Clopaz include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Clopaz. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Clopaz?

  • Store Clopaz at room temperature between 68°F to 77°F (20°C to 25°C).
  • Do not refrigerate or freeze Clopaz.
  • Protect Clopaz from light.
  • Shake your Clopaz bottle well for 10 seconds before each use.

Keep Clopaz and all medicines out of the reach of children.

General information about the safe and effective use of Clopaz

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use Clopaz for a condition for which it was not prescribed. Do not give Clopaz to other people, even if they have the same symptoms that you have. It may harm them.

This Patient Information Leaflet summarizes the most important information about Clopaz. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for more information about Clopaz that is written for healthcare professionals.

For more information, go to www. VERSACLOZ.com or call 1-800-520-5568.

What are the ingredients in Clopaz?

Active ingredient: Clopaz

Inactive ingredients: glycerin, sorbitol (non-crystallizing), sodium dihydrogen phosphate dihydrate, xanthan gum, sodium methylparaben, sodium propylparaben, povidone, water, and sodium hydroxide

Instructions for Use

Clopaz® (VER sa kloz)

(clozapine)

Oral Suspension

Supplies you will need to take your Clopaz dose:

  • Clopaz® Oral Suspension bottle
  • a bottle neck adaptor
  • the correct oral syringe to measure your dose
    • If your dose is 1 mL (50 mg) or less, use the smaller 1 mL oral syringe.
    • If your dose is more than 1 mL (50 mg), use the larger 9 mL oral syringe.

Disposal of your oral syringe, empty Clopaz bottle and bottle neck adaptor:

Place the cap back on the empty Clopaz bottle before you throw it away. The oral syringe, empty bottle and bottle neck adaptor should be placed in your household trash when you finish your bottle of Clopaz. The oral syringe should not be shared with other people or used for medicines other than Clopaz.

Distributed by:

Jazz Pharmaceuticals, Inc.

Palo Alto, CA 94304 USA

This Patient Information and the Instructions for Use have been approved by the U.S. Food and Drug Administration.

Revised: February 2017

symptoms of myocarditis and cardiomyopathy symptoms side effects Figure-03 Patient Use Figure A Step 1 Figure B Step 2 Figure C Step 3 Figure D-01 Figure D-02 Step 4 Figure E Step 5 Figure F Step 6 Figure G Step 7 Figure H Step 8 Figure I Step 9 Figure J Step 10 Figure K Step 11 Figure L Step 12 Figure M Step 13 Figure N Step 14

Rx Only

Clopaz®

(clozapine) Oral Suspension

50 mg/mL

Clopaz pharmaceutical active ingredients containing related brand and generic drugs:

infoActive ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Clopaz available forms, composition, doses:

infoForm of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Clopaz destination | category:

infoDestination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Clopaz Anatomical Therapeutic Chemical codes:

infoA medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Clopaz pharmaceutical companies:

infoPharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."VERSACLOZ (CLOZAPINE) SUSPENSION [JAZZ PHARMACEUTICALS, INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. Dailymed."CLOZAPINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  3. "clozapine". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Clopaz?

Depending on the reaction of the Clopaz after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Clopaz not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Clopaz addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sDrugs.com conducted a study on Clopaz, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Clopaz consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 15 here

The information was verified by Dr. Arunabha Ray, MD Pharmacology

© 2002 - 2019 "sDrugs.com". All Rights Reserved